In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 30, No. 15_suppl ( 2012-05-20), p. e14128-e14128
Abstract:
e14128 Background: Recently, bevacizuamb induced hypertension was suggested as being a predictive factor for bevacizumab in metastatic colorectal cancer (mCRC) patients. However, there wasn’t any useful pretreatment predictive factor for bevacizumab in our clinic. So, in this study, we investigated the predictive factors for bevacizumab in mCRC. Methods: From 2002 to 2011, thirty mCRC patients received bevacizumab containing chemotherapy in Kyung HeeUniversity Hospital, Seoul. Among them, 27 patients had a measurable disease which adequate for response evaluation using Response Evaluation Criteria for Solid Tumors. We analyzed predictive factors for bevacizumabin these 27 patients using chi-squaretest and binary logistic regression analysis. Results: Median age was 57.0. Thirteen patients (48.1%) were male. ECOG performance status was 0,1,2 (29.6%/59.3%/11.1%). Eight patients had right side tumor and nineteen patients had left sided tumor. Fifteen patients had two metastatic sites. Sixteen patients received bevacizumab containing chemotherapy as first or second line treatment. Fourteen patients received oxaliplatin based chemotherapy with bevacizumab. We analyzed predictive factors for bevacizumab containing chemotherapy. In the univariate analysis, response rate was higher (53.8% vs 14.3%) in male patients (p= 0.092, Fisher’s exact test). In the multivariate analysis (binary logistic regression analysis), gender was a significant predictive factor (p=0.046). Progression-free survival was 6.3 months (CI 95% :2.14 – 10.46 months) and 5.2 months (CI 95% : 3.92 –6.49 months) in male and female patients, respectively (log-rank, p=0.503). Overall survival was 9.4 months (CI 95% :7.2 – 11.63 months) and 11.7 months (CI 95% :10.3 – 13.08 months) in male and female patients, respectively (log-rank, p=0.773). Conclusions: Although sex is not a modifiable predictive factor, it appears that sex is an important predictive factor in metastatic colorectal cancer patients treated with bevacizumab containing chemotherapy.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2012.30.15_suppl.e14128
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2012
detail.hit.zdb_id:
2005181-5
